The Evolving Role of Nivolumab in Non–Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

2016 ◽  
Vol 17 (3) ◽  
pp. 161-168 ◽  
Author(s):  
Cesare Gridelli ◽  
Benjamin Besse ◽  
Julie Renee Brahmer ◽  
Lucio Crinò ◽  
Enriqueta Felip ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Treatment Algorithms ◽  
International Experts

scholarly journals Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us

2015 ◽  
Vol 18 (7) ◽  
pp. A457-A458 ◽  
Author(s):  
C Graham ◽  
H Knox ◽  
LM Hess ◽  
M Jen ◽  
G Cuyun Carter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
The Us

scholarly journals PCN67 Erlotinib as Second Line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC): Economic Modeling (EM) results

2011 ◽  
Vol 14 (7) ◽  
pp. A446 ◽  
Author(s):  
E.A.V. Santos ◽  
C.T. Buschinelli ◽  
M. Ferracini ◽  
C. Pepe ◽  
M. Estanislao
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Economic Modeling ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document